Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax, Lenalidomide, and Rituximab in Previously Untreated Mantle Cell Lymphoma
NCT03523975Phase 2Recruiting
- Sponsor
- City of Hope
- Start
- Dec 2018
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of venetoclax in mantle cell lymphoma (MCL), sponsored by City of Hope. Started Dec 2018; status: recruiting.
02
Drugs
venetoclax
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT03523975.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03523975.